← Leaderboards
Biana Godin
Nano3d Biosciences, Inc.
$753,648
Attributed
$1,570,786
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $444.1K · FY2014–22$500K$375K$250K$125K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$1,570,786 · 4
By mechanism
R21$1,380,318 · 3
R41$190,468 · 1
Top collaborators
- Jerrie Selga Refuerzo3 shared
- Soumya Chatterjee1 shared
- Chinnaswamy Jagannath1 shared
- Glauco Ranna Souza1 shared
- Sonia Villapol1 shared
Most similar at Nano3d Biosciences, Inc.
Same institution · by research overlap
- Jerrie Selga Refuerzo$279,218
- Glauco Ranna Souza$138,489
Others in their field
Top investigators on “In Vivo”
- David Heimbrook · Leidos Biomedical Research, Inc.$371,850,582
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Dennis R. Burton · Scripps Research Institute$212,708,174
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$98,374,200
Research focus
In VivoTissuesPharmaceutical PreparationsBaseSurfaceToxic EffectDesignBiodistributionLiposomesCellsAnimalsEvaluationNanovectorAreaNanomedicineOrganAffectLeadIndomethacinImpairmentInnovationModificationBindingBiomaterial Compatibility
Grant awards (6)
Intranasal Delivery of Telomerase Reverse Transcriptase mRNA for Therapy ofTraumatic Brain Injury$444,125
R21 · FY2022 · NS · contact PI
Evaluation of immune responses to CD44-targeted nanovectors for designing a novel anti-tuberculosis host-directed therapy$258,925
R21 · FY2020 · AI · contact PI
Study of responses to CD44 targeted nanovectors to design a novel adjunctive anti-tuberculosis host-directed therapy$245,811
R21 · FY2019 · AI
Development of Nanovectors to Prevent Placental Passage of a Tocolytic Agent$193,054
R21 · FY2016 · HD
Development of Nanovectors to Prevent Placental Passage of a Tocolytic Agent$238,403
R21 · FY2015 · HD
A novel 3D cell culture human uterine contractility assay for high-throughput scr$190,468
R41 · FY2014 · HD